Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2006

Open Access 01-12-2006 | Case report

Challenging the concept of microinvasive carcinoma of the vulva: report of a case with regional lymph node recurrence and review of the literature

Authors: Jutta Sidor, Raihana Diallo-Danebrock, Elke Eltze, Ralph J Lellé

Published in: BMC Cancer | Issue 1/2006

Login to get access

Abstract

Background

It is widely accepted that vulvar carcinoma with a depth of invasion of less than one millimeter is sufficiently treated by vulvectomy or wide local excision without inguinal lymphadenectomy.

Case presentation

However, a patient with inguinal lymph node recurrence 21 months after radical vulvectomy for stage IA squamous cell carcinoma was observed.

Conclusion

According to a review of the literature, there are five additional cases of metastasizing vulvar cancer with a depth of invasion of less than one millimeter. Therefore, the definition of microinvasive carcinoma of the vulva based on depth of invasion alone may not be as reliable as previously thought and does not rule out inguinal lymph node involvement or recurrence. Consequently, the necessity of inguinal node dissection for microinvasive carcinoma needs to be discussed on an individual basis taking into account the age of the patient as well as the potential morbidity of extended surgery.
Appendix
Available only for authorised users
Literature
1.
2.
Wilkinson EJ, Rico MJ, Pierson KK: Microinvasive carcinoma of the vulva. Int J Gynecol Pathol. 1982, 1 (1): 29-39.CrossRefPubMed
3.
Preti M, Rouzier R, Mariani L, Wilkinson EJ: Superficially invasive carcinoma of the vulva: diagnosis and treatment. Clin Obstet Gynecol. 2005, 48 (4): 862-868. 10.1097/01.grf.0000179668.14187.3a.CrossRefPubMed
4.
Volgger B, Marth C, Zeimet A, Muller-Holzner E, Ruth N, Dapunt O: Fulminant course of a microinvasive vulvar carcinoma in an immunosuppressed woman. Gynecol Oncol. 1997, 65 (1): 177-179. 10.1006/gyno.1997.4632.CrossRefPubMed
5.
Thangavelu A, Andrew A, Buxton EJ: Groin recurrence following Stage 1A squamous cell carcinoma of the vulva. Gynecol Oncol. 2006, 101 (1): 172-174. 10.1016/j.ygyno.2005.09.057.CrossRefPubMed
6.
Van Der Velden J, Kooyman CD, Van Lindert AC, Heintz AP: A stage Ia vulvar carcinoma with an inguinal lymph node recurrence after local excision. A case report and literature review. Int J Gynecol Cancer. 1992, 2 (3): 157-159. 10.1046/j.1525-1438.1992.02030157.x.CrossRefPubMed
7.
Atamdede F, Hoogerland D: Regional lymph node recurrence following local excision for microinvasive vulvar carcinoma. Gynecol Oncol. 1989, 34 (1): 125-128. 10.1016/0090-8258(89)90123-6.CrossRefPubMed
8.
Hicks ML, Hempling RE, Piver MS: Vulvar carcinoma with 0.5 mm of invasion and associated inguinal lymph node metastasis. J Surg Oncol. 1993, 54 (4): 271-273.CrossRefPubMed
9.
Benedet JL, Bender H, Jones H, Ngan HY, Pecorelli S: FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obstet. 2000, 70 (2): 209-262. 10.1016/S0020-7292(00)00300-3.CrossRefPubMed
10.
Pinto AP, Schlecht NF, Pintos J, Kaiano J, Franco EL, Crum CP, Villa LL: Prognostic significance of lymph node variables and human papillomavirus DNA in invasive vulvar carcinoma. Gynecol Oncol. 2004, 92 (3): 856-865. 10.1016/j.ygyno.2003.11.052.CrossRefPubMed
11.
Magrina JF, Gonzalez-Bosquet J, Weaver AL, Gaffey TA, Leslie KO, Webb MJ, Podratz KC: Squamous cell carcinoma of the vulva stage IA: long-term results. Gynecol Oncol. 2000, 76 (1): 24-27. 10.1006/gyno.1999.5638.CrossRefPubMed
12.
Dhar KK, Woolas RP: Changes in the management of vulval cancer. Best Pract Res Clin Obstet Gynaecol. 2003, 17 (4): 529-542. 10.1016/S1521-6934(03)00044-0.CrossRefPubMed
13.
Borgno G, Micheletti L, Barbero M, Cavanna L, Preti M, Valentino MC, Ghiringhello B, Bocci A: Topographic distribution of groin lymph nodes. A study of 50 female cadavers. JReprodMed. 1990, 35 (12): 1127-1129.
14.
Micheletti L, Levi AC, Bogliatto F: Anatomosurgical implications derived from an embryological study of the Scarpa's triangle with particular reference to groin lymphadenectomy. Gynecol Oncol. 1998, 70 (3): 358-364. 10.1006/gyno.1998.5073.CrossRefPubMed
15.
Hudson CN, Shulver H, Lowe DC: The surgery of 'inguino-femoral' lymph nodes: is it adequate or excessive?. Int J Gynecol Cancer. 2004, 14 (5): 841-845. 10.1111/j.1048-891X.2004.14518.x.CrossRefPubMed
16.
Sliutz G, Reinthaller A, Lantzsch T, Mende T, Sinzinger H, Kainz C, Koelbl H: Lymphatic mapping of sentinel nodes in early vulvar cancer. Gynecol Oncol. 2002, 84 (3): 449-452. 10.1006/gyno.2001.6572.CrossRefPubMed
17.
Terada KY, Shimizu DM, Jiang CS, Wong JH: Outcomes for patients with T1 squamous cell cancer of the vulva undergoing sentinel node biopsy. Gynecol Oncol. 2006
Metadata
Title
Challenging the concept of microinvasive carcinoma of the vulva: report of a case with regional lymph node recurrence and review of the literature
Authors
Jutta Sidor
Raihana Diallo-Danebrock
Elke Eltze
Ralph J Lellé
Publication date
01-12-2006
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2006
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-6-157

Other articles of this Issue 1/2006

BMC Cancer 1/2006 Go to the issue

Research article

Chemoresistance induces enhanced adhesion and transendothelial penetration of neuroblastoma cells by down-regulating NCAM surface expression

Research article

Mismatch repair and treatment resistance in ovarian cancer

Research article

Prognostic value of p27Kip1expression in Basaloid Squamous Cell Carcinoma of the larynx

Research article

Signs of positive selection of somatic mutations in human cancers detected by EST sequence analysis

Research article

A phase II trial of a biweekly combination of paclitaxel and gemcitabine in metastatic breast cancer

Research article

Increased mRNA expression levels of ERCC1, OGG1 and RAIin colorectal adenomas and carcinomas
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits